- Free Writing Prospectus - Filing under Securities Act Rules 163/433 (FWP)
07 Outubro 2009 - 7:19AM
Edgar (US Regulatory)
Issuer Free Writing Prospectus
Filed pursuant to Rule 433
Registration Statement No. 333-160679
(Supplementing Preliminary Prospectus Supplement
dated October 5, 2009)
14,000,000 Shares
Allos Therapeutics, Inc.
Common Stock
This
free writing prospectus relates only to the securities described below and
should be read together with the preliminary prospectus supplement dated October 5,
2009 (including the base prospectus dated August 28, 2009 and the
documents incorporated by reference therein) relating to these securities.
Terms and Conditions of the Common
Stock Offering
Number
of Shares of Common Stock
|
|
14,000,000
|
|
|
|
Overallotment
Option
|
|
2,100,000
|
|
|
|
Public
Offering Price per Share
|
|
$7.10
|
|
|
|
Underwriting
Discounts and Commissions per Share
|
|
$0.40825
|
|
|
|
Proceeds
|
|
Approximately $93.0
million, or approximately $107.1 million if the underwriters over-allotment
option is exercised in full, after deducting the underwriting discounts and
commissions and estimated offering expenses.
|
|
|
|
Dilution
|
|
Allos
net tangible book value at June 30, 2009 was approximately
$100.6 million, or $1.13 per share. After giving effect to the sale of
14,000,000 shares of common stock by Allos at the offering price of $7.10 per
share, less underwriting
discounts and commissions and estimated offering expenses payable by Allos,
Allos net tangible book value at June 30, 2009, would have been
approximately $193.6 million, or $1.87 per share. This represents an
immediate increase in the net tangible book value of $0.74 per share to
existing Allos stockholders and an immediate dilution of $5.23 per share to
investors in this offering.
If the underwriters over-allotment option is exercised in full, Allos pro
forma net tangible book value per share after giving effect to this offering
would be $1.97 per share, and the dilution in pro forma net tangible book
value per share to investors in this offering would be $5.13 per share.
|
|
|
|
Trade
Date
|
|
October 7, 2009
|
|
|
|
Settlement
Date
|
|
October 13, 2009
|
|
|
|
Underwriters
|
|
J.P. Morgan Securities Inc., Citigroup Global Markets Inc.,
Leerink Swann LLC, JMP Securities LLC,
Needham & Company, LLC and RBC Capital Markets.
|
The
issuer has filed a registration statement (including a prospectus and
preliminary prospectus supplement thereto) with the Securities and Exchange
Commission, or SEC, for the offering to which this communication relates.
Before you invest, you should read the prospectus and preliminary prospectus
supplement in that registration statement (including the documents incorporated
by reference therein) and other documents the issuer has filed with the SEC for
more complete information about the issuer and this offering. You may get these
documents for free by visiting EDGAR on the SECs web site at www.sec.gov.
Alternatively, the issuer, any underwriter or any dealer participating in the
offering will arrange to send you the prospectus and preliminary prospectus
supplement if you request it by calling J.P.
Morgan Securities Inc. at (718) 242-8002 or Citigroup Global Markets Inc. at
(800) 831-9146.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de